RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MASSAIA M
Collezione AO Ordine Mauriziano

Items : 6

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications. in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis / Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221125785. doi: 10.1177/10760296221125785.

2022
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Massaia M; Bruno B; Borchiellini A; Porreca A; Montaruli B; Sivera P; Pizzo E; Valpreda A; Valeri F; Dainese C;

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. in Oncoimmunology / Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

2018
AO Ordine Mauriziano

Circosta P; Elia AR; Landra I; Machiorlatti R; Todaro M; Aliberti S; Brusa D; Deaglio S; Chiaretti S; Bruna R; Gottardi D; Massaia M; Giacomo FD; Guarini AR; Foà R; Kyriakides PW; Bareja R; Elemento O; Chichili GR; Monteleone E; Moore PA; Johnson S; Bonvini E; Cignetti A; Inghirami G;

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. in Haematologica / Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Piciocchi A; Boncompagni R; Orlando S; Cuneo A; Galieni P; Marasca R; Vannata B; Pozzato G; Efremov DG; Molica S; Coscia M; Massaia M; D'Arena G; Del Poeta G; Mannina D; Mauro FR; Ciolli S; Autore F; Innocenti I; Laurenti L; Vincelli D; Liberati AM; Russo F; Foá R; Laurenti L; Innocenti I; Autore F; Ciolli S; Mauro FR; et alii...

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). in Leukemia & lymphoma / Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6.

2016
AO Ordine Mauriziano

Bruno B; Auner HW; Gahrton G; Garderet L; Festuccia M; Ladetto M; Lemoli RM; Massaia M; Morris C; Palumbo A; Schönland S; Boccadoro M; Kröger N;

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. in Blood / Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

2015
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Gaidano G; Gattei V; Foà R; Cuneo A; Montillo M; Massaia M; Zinzani PL; Del Poeta G; Perbellini O; Moreno C; Marasca R; Tedeschi A; Neri A; Motta M; Coscia M; Rigolin GM; Vincelli I; Del Giudice I; Gentile M; Laurenti L; Forconi F; Zaja F; Morabito F; Cortelezzi A; Mauro FR; Visco C; Chiarenza A; Bulian P; Ghilardi G; et alii...